Intravenous Lidocaine Response as a Predictor for Oral Oxcarbazepine Efficacy in Neuropathic Pain Syndrome: A Prospective Cohort Study

Sukunya Jirachaipitak; Pramote Euasobhon; Suthanee Cenpakdee; Suratsawadee Wangnamthip; Pranee Rushatamukayanunt

doi:10.12659/MSM.945612

19 September 2024 : Clinical Research

Intravenous Lidocaine Response as a Predictor for Oral Oxcarbazepine Efficacy in Neuropathic Pain Syndrome: A Prospective Cohort Study

Sukunya Jirachaipitak^1ABCDEF, Pramote Euasobhon^1ABCDEFG*, Suthanee Cenpakdee^1ABEF, Suratsawadee Wangnamthip^1ABDE, Pranee Rushatamukayanunt^1ABDE

DOI: 10.12659/MSM.945612

Med Sci Monit 2024; 30:e945612

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Predictive value of lidocaine infusion for oxcarbazepine treatment. The data are presented as percentages and 95% CI.

	Percentages	95% CI
Positive predictive value	54.6	32.0–75.4
Negative predictive value	76.2	61.6–86.5

Back to the Article

Intravenous Lidocaine Response as a Predictor for Oral Oxcarbazepine Efficacy in Neuropathic Pain Syndrome: A Prospective Cohort Study

Your Privacy